Literature DB >> 18438525

The natural history of type 1A diabetes.

George S Eisenbarth1, Joy Jeffrey.   

Abstract

We can now predict the development of Type 1A (Immune Mediated) diabetes primarily through the determination of four biochemically characterized islet autoantibodies [insulin, GAD65, IA-2 (ICA512) and (Znt8)]. Prediction is possible because beta-cell destruction is chronically progressive and very slow in most, but not all individuals. We can also prevent type 1A diabetes in animal models and a major goal is the prevention of type 1A diabetes in man with multiple clinical trials underway.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18438525     DOI: 10.1590/s0004-27302008000200002

Source DB:  PubMed          Journal:  Arq Bras Endocrinol Metabol        ISSN: 0004-2730


  16 in total

1.  Serum titres of anti-glutamic acid decarboxylase-65 and anti-IA-2 autoantibodies are associated with different immunoregulatory milieu in newly diagnosed type 1 diabetes patients.

Authors:  M Andrade Lima Gabbay; M N Sato; A J S Duarte; S A Dib
Journal:  Clin Exp Immunol       Date:  2012-04       Impact factor: 4.330

2.  2α-Methyl-19-nor-(20S)-1,25-dihydroxyvitamin D(3) protects the insulin 2 knockout non-obese diabetic mouse from developing type 1 diabetes without hypercalcaemia.

Authors:  C M Kiekhaefer; B Weber; M Huggins; C Gorichanaz; J A Nehring; H F DeLuca
Journal:  Clin Exp Immunol       Date:  2011-12       Impact factor: 4.330

3.  Dysregulated Toll-like receptor-induced interleukin-1β and interleukin-6 responses in subjects at risk for the development of type 1 diabetes.

Authors:  Aimon K Alkanani; Marian Rewers; Fran Dong; Kathleen Waugh; Peter A Gottlieb; Danny Zipris
Journal:  Diabetes       Date:  2012-06-29       Impact factor: 9.461

4.  Insulin receptor substrate-2 in beta-cells decreases diabetes in nonobese diabetic mice.

Authors:  Lisa D Norquay; Katharine E D'Aquino; Lynn M Opare-Addo; Alexandra Kuznetsova; Michael Haas; Jeffrey A Bluestone; Morris F White
Journal:  Endocrinology       Date:  2009-07-02       Impact factor: 4.736

5.  Autoimmunity against INS-IGF2 protein expressed in human pancreatic islets.

Authors:  Norio Kanatsuna; Jalal Taneera; Fariba Vaziri-Sani; Nils Wierup; Helena Elding Larsson; Ahmed Delli; Hanna Skärstrand; Alexander Balhuizen; Hedvig Bennet; Donald F Steiner; Carina Törn; Malin Fex; Åke Lernmark
Journal:  J Biol Chem       Date:  2013-08-09       Impact factor: 5.157

6.  Attacking the source: anti-PDX-1 responses in type 1 diabetes.

Authors:  Yaima Luzardo; Clayton Elwood Mathews
Journal:  Lab Invest       Date:  2010-01       Impact factor: 5.662

7.  Zinc transporter 8 autoantibodies and their association with SLC30A8 and HLA-DQ genes differ between immigrant and Swedish patients with newly diagnosed type 1 diabetes in the Better Diabetes Diagnosis study.

Authors:  Ahmed J Delli; Fariba Vaziri-Sani; Bengt Lindblad; Helena Elding-Larsson; Annelie Carlsson; Gun Forsander; Sten A Ivarsson; Johnny Ludvigsson; Ingrid Kockum; Claude Marcus; Ulf Samuelsson; Eva Örtqvist; Leif Groop; George P Bondinas; George K Papadopoulos; Åke Lernmark
Journal:  Diabetes       Date:  2012-07-10       Impact factor: 9.461

8.  New directions for research into type 1 diabetes in India--an immunological perspective.

Authors:  Ranjit Unnikrishnan; Viswanathan Mohan
Journal:  Indian J Med Res       Date:  2014-09       Impact factor: 2.375

9.  Etiopathogenesis of insulin autoimmunity.

Authors:  Norio Kanatsuna; George K Papadopoulos; Antonis K Moustakas; Ake Lenmark
Journal:  Anat Res Int       Date:  2012-02-22

10.  CD226 rs763361 is associated with the susceptibility to type 1 diabetes and greater frequency of GAD65 autoantibody in a Brazilian cohort.

Authors:  Teresa Cristina Colvara Mattana; Aritania Sousa Santos; Rosa Tsuneshiro Fukui; Debora Teixeira Oliveira Mainardi-Novo; Vinícius Silva Costa; Rosa Ferreira Santos; Sergio Russo Matioli; Maria Elizabeth Rossi da Silva
Journal:  Mediators Inflamm       Date:  2014-05-07       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.